daiichisankyo.us Open in urlscan Pro
52.168.54.37  Public Scan

Form analysis
1 forms found in the DOM

Name: hrefFm — POST #

<form action="#" id="hrefFm" method="post" name="hrefFm"><span></span></form>

Text Content

Skip to content
Passion for innovation. Compassion for Patients.
Healthcare Professionals | Careers | Contact Us | Worldwide |
Search Search Search

 * About Us
   * About Us
   
   
   * WHO WE ARE
     
     * Values and Mission
     * Company Culture
     * Global Business Strategy and Midterm Plan
     * History
     * Corporate Philanthropy
   
   
   * PARTNERING
     
     * Business Development
   
   
   * CORPORATE INFORMATION
     
     * Corporate Management
     * Company Governance and Global Structure
     * Corporate Brochure
   
   
   * PATIENT ADVOCACY
 * Responsibility
   * Responsibility
   
   
   * COMPLIANCE
     
     * Standards Of Business Conduct
     * Standards of Business Conduct & Ethics for Third Parties
     * Daiichi Sankyo Group Global Anti-Bribery and Anti-Corruption Policy
     * California Compliance Declaration
     * California Supply Chains Act
     * Daiichi Sankyo Group Employee Code of Conduct
   
   
   * TRANSPARENCY AND DISCLOSURE
     
     * Post-marketing Commitments
     * CME and Charitable Contributions Disclosure
     * Working with Healthcare Professionals
     * Vermont Pharmaceutical Marketer Price Disclosure
     * Clinical Trial Information Disclosure
   
   
   * CORPORATE GIVING AND SUPPORT
     
     * Daiichi Sankyo Requirements
     * Charitable Contributions
     * Sponsorships
     * Corporate Support FAQs
     * Patient Advocacy Support
     * Independent Medical Education (IME)
   
   
   * DAIICHI SANKYO PATIENT SUPPORT PROGRAMS
   
   
   * SUPPLIER DIVERSITY
     
     * Supplier Registration
     * Supplier Diversity FAQs
   
   
   * TRANSPARENCY IN COVERAGE
   
   
   * RIGHTS & PROTECTIONS AGAINST SURPRISE MEDICAL BILLS
 * Research & Development
   * Research & Development
   * Our Pipeline
   * Worldwide R&D Operations
   * Clinical Trial Information Disclosure
   
   
   * EXPANDED ACCESS TO INVESTIGATIONAL PRODUCTS
   
   * External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and
     Collaborative Research (CR)
 * Medicines
 * Media
 * Our Stories


Search Search Button
 * 
   About Us
   * 
     Who We Are
     * Who We Are
     * Values and Mission
     * Company Culture
     * Global Business Strategy and Midterm Plan
     * History
     * Corporate Philanthropy
   * 
     Partnering
     * Partnering
     * Business Development
   * 
     Corporate Information
     * Corporate Information
     * Corporate Management
     * Company Governance and Global Structure
     * Corporate Brochure
   * Patient Advocacy
 * 
   Responsibility
   * 
     Compliance
     * Compliance
     * Standards Of Business Conduct
     * Standards of Business Conduct & Ethics for Third Parties
     * Daiichi Sankyo Group Global Anti-Bribery and Anti-Corruption Policy
     * California Compliance Declaration
     * California Supply Chains Act
     * Daiichi Sankyo Group Employee Code of Conduct
   * 
     Transparency and Disclosure
     * Transparency and Disclosure
     * Post-marketing Commitments
     * CME and Charitable Contributions Disclosure
     * Working with Healthcare Professionals
     * Vermont Pharmaceutical Marketer Price Disclosure
     * Clinical Trial Information Disclosure
   * 
     Corporate Giving and Support
     * Corporate Giving and Support
     * Daiichi Sankyo Requirements
     * Charitable Contributions
     * Sponsorships
     * Corporate Support FAQs
     * Patient Advocacy Support
     * Independent Medical Education (IME)
   * Daiichi Sankyo Patient Support Programs
   * 
     Supplier Diversity
     * Supplier Diversity
     * Supplier Registration
     * Supplier Diversity FAQs
   * Transparency in Coverage
   * Rights & Protections Against Surprise Medical Bills
 * 
   Research & Development
   * Our Pipeline
   * Worldwide R&D Operations
   * Clinical Trial Information Disclosure
   * Expanded Access to Investigational Products
   * External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and
     Collaborative Research (CR)
 * Medicines
 * Media
 * Our Stories
 * Healthcare Professionals
 * Careers
 * Contact Us


HOME_PAGE_HEADER_CONTENT

Passion for Innovation.

Compassion for Patients.




LEARN MORE-HP UPDATED


LEARN MORE

Your browser does not support the video tag.

Corporate Video

For people affected by cancer, Daiichi Sankyo turns hope into possibility.
Possibility into reality. Our collective craft is medicine. We’re transforming
how cancer and other disease are treated. More than 120 year of heritage
inspires us to meet new challenges.

 
Daiichi Sankyo’s HER2 Directed ADC Receives Industry’s Top Award

The Galien Foundation has recognized Daiichi Sankyo’s HER2 directed antibody
drug conjugate (ADC) with the prestigious 2024 Prix Galien USA Award for Best
Biotechnology Product. read more

 
Translating Science for Patients—The Craft of a Passionate Advocate

For cancer patients, the science concerning their disease is sometimes outside
of reach. As a patient-centric organization, we are on a mission to break down
those barriers. read more

 
Biomarker Testing and the Power of Information

Cancer remains one of the most challenging diseases in the world today, but
critical advances in science are transforming options for more personalized
treatment. read more




FEATURED NEWS


PRESS RELEASES

Email Alert
November 13, 2024 NEW
Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant
Cell Tumor at CTOS Download
November 12, 2024 NEW
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S.
for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung
Cancer Download
November 08, 2024 NEW
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology
Product Download
Oktober 30, 2024 NEW
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in
Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Download
View All



 * ABOUT US
   
   * Who We Are
   * Partnering
   * Corporate Information
   * Patient Advocacy


 * RESPONSIBILITY
   
   * Compliance
   * Transparency and Disclosure
   * Corporate Giving and Support
   * Daiichi Sankyo Patient Support Programs
   * Supplier Diversity
   * Transparency in Coverage
   * Rights & Protections Against Surprise Medical Bills


 * RESEARCH & DEVELOPMENT
   
   * Our Pipeline
   * Worldwide R&D Operations
   * Clinical Trial Information Disclosure
   * Expanded Access to Investigational Products
   * External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and
     Collaborative Research (CR)
 * Medicines
 * Media
 * Our Stories

 * LinkedIn
 * Twitter
 * Facebook
 * Youtube

   
 * Terms & Conditions
 * Privacy Notice
 * Contact Us
 * Site Map

© 2024 Daiichi Sankyo, Inc. All Rights Reserved.
go to top


WORLDWIDE

Daiichi Sankyo Co., Ltd - Global


ASIA

 * Japan
 * China
 * Hong Kong
 * Korea
 * Taiwan
 * Thailand
 * Vietnam


AMERICAS

 * Brazil

USA

 * Daiichi Sankyo, Inc.
 * American Regent, Inc.
 * Plexxikon


EUROPE

 * Daiichi Sankyo
   Europe
 * Austria
 * Belgium
 * France
 * Germany
 * Ireland

 * Italy
 * Portugal
 * Spain
 * Switzerland
 * The Netherlands
 * Turkey
 * United Kingdom



Continue Return